Submit to Applied Sciences Review for Applied Sciences Propose a Special Issue

Journal Menu

Journal Browser

Treatment of Cell Tumor Based on Morpho-Functional and Histology

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Benefits of Publishing in a Special Issue
Published Papers

A special issue of Applied Sciences (ISSN 2076-3417). This special issue belongs to the section "Applied Biosciences and Bioengineering".

Deadline for manuscript submissions: closed (30 January 2022) | Viewed by 15419

Share This Special Issue

Special Issue Editor

Prof. Dr. Carmen Lacramioara Zamfir

E-Mail Website
Guest Editor

Morpho-Functional Sciences Department, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, Romania
Interests: oxidative stress; target therapy; antioxidants; nanomedicine; drug resistance; animal experimental models

Special Issue Information

Dear Colleagues,

One of the central goals for the treatment of cell tumor is to correlate the cellular morpho-functional status with a drug response and at the same time to detect the possibility of the development of resistance. The tumor therapeutic management strategy is still a challenge, especially when we refer to target therapies, and in many cases, it is reasonable to refer to a multimodality approach in treating cancer. Tumor therapeutic design must be firmly correlated with an accurate and clearly precise histology. The objective of this Special Issue is to focus on the efficiency of treatment, exploring histological specific features of the cellular profile, as an integrant component of the precise approach for ulterior tumor treatment strategy.

Based on increasingly accumulating data on histology driven therapy significance for tumor cells, we endorse that it is an actual demand to highlight the prognostic and predictive role of histology.

We consider that new results have to be mentioned to further understand and encourage discussions about the effectiveness of histology in initiating of promising new treatment options, in an adequate cooperation with other specialists.

Prof. Dr. Carmen Lacramioara Zamfir
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

tumor cell treatment
cytotoxics
histology
target therapy
drug response
molecular profile
molecular pattern
drug resistance
multimodality treatment
morpho-functional cell status

Benefits of Publishing in a Special Issue

Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (4 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Jump to: Review

11 pages, 11071 KiB

Open AccessArticle

Ovarian Masses-Applicable IOTA ADNEX Model versus Morphological Findings for Accurate Diagnosis and Treatment

by Tudor Butureanu, Demetra Socolov, Daniela Roxana Matasariu, Alexandra Ursache, Ana-Maria Apetrei, Irina Dumitrascu, Ingrid Vasilache, Dorina Rudisteanu, Vasile Lucian Boiculese and Ludmila Lozneanu

Appl. Sci. 2021, 11(22), 10789; https://doi.org/10.3390/app112210789 - 15 Nov 2021

Cited by 3 | Viewed by 3438

Abstract

A common problem in gynecological practice is the differential diagnosis of the ovarian masses. The clinician must apply the IOTA (International Ovarian Tumor Analysis) ADNEX (Assessment of Different Neoplasia in the Adnexa) model criteria to evaluate the risk of benign, borderline or malignant tumors. The aim of this study was to verify if the IOTA ADNEX model is a practical tool to be used before surgery and if there is a significant difference between IOTA ADNEX criteria and histological findings. A prospective single center study was performed between January 2017 and December 2019 in Obstetrics and Gynecology Hospital “Cuza-Voda”, Iasi, Romania. The study included 230 patients between 17 and 74 years old diagnosed with persistent adnexal masses. We applied the IOTA ADNEX model protocol predicting the risk of benign, borderline or malignant masses. The golden standard remains the histological diagnosis of the surgically removed mass. The patients that had been diagnosed using ultrasonography with persistent adnexal masses between 30 and 291 mm were operated on in our clinic. In our study. the majority of patients had benign ovarian tumor mass, these being 223 (96.96%) patients, from whom, according to IOTA ADNEX protocol, the correspondence was: 91.8–99.7% at risk of benign tumors, 0.3–4.5% at risk of borderline tumors and 0.3–8.2% at risk of malignant masses. Unexpected findings were obtained from the malignant group that included five patients (2.17%) with the following correspondence: 96.1–99% at risk of benign tumors, 0.6–2.4% at risk of borderline tumors and 1–3.9% at risk of malignant masses. After applying the IOTA ADNEX model criteria, the patients with a suspicion of malignant disease were correctly guided towards surgical treatment in an oncological center. In our hospital, surgical treatment was only proposed to those patients with high suspicion of benign masses. Full article

(This article belongs to the Special Issue Treatment of Cell Tumor Based on Morpho-Functional and Histology)

► Show Figures

Figure 1

11 pages, 4028 KiB

Open AccessArticle

Struma Ovarii: Clinico-Morphological Features and Therapeutic Experience of a Romanian Institution over 20 Years

by Mihaela Camelia Tîrnovanu, Vlad Gabriel Tîrnovanu, Bogdan Florin Toma, Elena Cojocaru, Carmen Ungureanu, Cătălina Barbăroșie and Ludmila Lozneanu

Appl. Sci. 2021, 11(20), 9427; https://doi.org/10.3390/app11209427 - 11 Oct 2021

Cited by 1 | Viewed by 2949

Abstract

Struma ovarii is a rare condition with scarce published data regarding clinical, morphological, and therapeutic approaches. This study reports the experience of 25 patients with struma ovarii who received surgical treatment in a gynecology department in Romania. The study was conducted from January 1999 to September 2021 and included patients with confirmed struma ovarii whose medical records were retrospectively reviewed and evaluated. Struma ovarii represented 2.8% of the total number of benign ovarian tumors treated by surgery. The age of the patients was between 24 and 71 years. The tumor was unilateral in 24 cases, 13 cases on the left ovary, 11 on the right side, and bilateral in 1 case. Tumor dimensions ranged between 1 cm and 20 cm. In two cases, the patients had symptoms of hyperthyroidism. The procedure was performed on four women for diagnoses other than an ovarian tumor. In another five situations, there was suspicion of ovarian malignancy. In addition, struma ovarii was associated with other clinical conditions in 22 cases. These lesions represent a diagnostic challenge with heterogeneous clinical and imaging manifestations. Complete information of clinical, morphologic, and surgical findings may improve the diagnostic algorithm and better predict patient outcomes. Full article

(This article belongs to the Special Issue Treatment of Cell Tumor Based on Morpho-Functional and Histology)

► Show Figures

Figure 1

8 pages, 1795 KiB

Open AccessArticle

Non-Melanoma Facial Skin Tumors—The Correspondence between Clinical and Histological Diagnosis

by Camelia Tamas, Irina Mihaela Jemnoschi Hreniuc, Angela Tecuceanu, Bogdan Mihnea Ciuntu, Clara Larisa Ibanescu, Ioana Tamas, Victor Ianole, Cristina Stanescu, Catalina Teodora Pintilie, Carmen Lacramioara Zamfir and Dan Cristian Moraru

Appl. Sci. 2021, 11(16), 7543; https://doi.org/10.3390/app11167543 - 17 Aug 2021

Cited by 1 | Viewed by 2528

Abstract

This paper consists of a retrospective study that includes a total of 186 cases with facial skin tumors diagnosed and treated between January 2015 and December 2017. Our aim was to correlate the initial clinical diagnosis with the histological results, in order to observe the success rate of our clinical experience, but also to underline that certain clinical tumor aspects can be misleading as the histological findings can result in different final diagnostics. From the total number of cases, we counted a total of 226 tumors (both benign and malignant), from which 194 had the clinical diagnosis confirmed by the anatomopathological exam and 34 had a different laboratory result from the clinical presumption: 10 benign tumors and 22 malignant tumors (eight BCC and 14 SCC, 12 of the latter being confused with ulcerovegetant BCC). Detailed correlation data were presented, as well as different situations of incongruence between the clinical and the histological diagnosis. The long-term goal of the study was to use our experience of correlating the clinical and the histological diagnosis, in order to improve the existing knowledge on the clinical differential diagnosis of both malignant and benign facial skin tumors. Full article

(This article belongs to the Special Issue Treatment of Cell Tumor Based on Morpho-Functional and Histology)

► Show Figures

Figure 1

Review

Jump to: Research

10 pages, 3308 KiB

Open AccessReview

Synovial Sarcoma of the Extremities: A Literature Review

by Cosmin Ioan Faur, Daniel Laurentiu Pop, Ahmed Abu Awwad, Carmen Lacramioara Zamfir, Roxana Folescu, Daniela Gurgus, Andrei Gheorghe Marius Motoc, Jenel Marian Patrascu, Sorin Bogdan Motoi, Oana Belei and Ana Maria Ungureanu

Appl. Sci. 2021, 11(16), 7407; https://doi.org/10.3390/app11167407 - 12 Aug 2021

Cited by 9 | Viewed by 5640

Abstract

Synovial sarcoma (SS) is a rare and highly malignant tumor and a type of soft tissue sarcoma (STS), for which survival has not improved significantly in recent years. Synovial sarcomas occur mostly in adolescents and young adults (15–35 years old), usually affecting the deep soft tissues near the large joints of the extremities, with males being at a slightly higher risk. Despite its name, synovial sarcoma is neither related to the synovial tissues that are a part of the joints, i.e., the synovium, nor does it express synovial markers; however, the periarticular synovial sarcomas can spread as a secondary tumor to the joint capsule. SS was initially described as a biphasic neoplasm comprising of both epithelial and uniform spindle cell components. Synovial sarcoma is characterized by the presence of the pathognomonic t (X; 18) (p11.2; q11.2) translocation, involving a fusion of the SS18 (formerly SYT) gene on chromosome 18 to one of the synovial sarcoma X (SSX) genes on chromosome X (usually SSX1 or SSX2), which is seen in more than 90% of SSs and results in the formation of SS18-SSX fusion oncogenes. Full article

(This article belongs to the Special Issue Treatment of Cell Tumor Based on Morpho-Functional and Histology)

► Show Figures

Journal Menu

Journal Browser

Treatment of Cell Tumor Based on Morpho-Functional and Histology

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Benefits of Publishing in a Special Issue

Published Papers (4 papers)

Research

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI